ZLAB
Zai Lab Limited
NASDAQ · Healthcare · Biotechnology · CN
$26.23
−2.85%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−15.3x
Market Cap
$2.94B
MomentumView details →
1D Return
−2.85%
YTD Return
+47.56%
RSI (14)
59.6
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−15.3x
Market Cap
$2.94B
RSI (14)
59.6
MomentumView details →
1D Return
−2.85%
YTD Return
+47.56%
SummaryUpdated Jun 1, 2026
Zai Lab Limited (NASDAQ:ZLAB) is a Chinese biopharmaceutical company founded in 2013 and headquartered in Shanghai. The company went public on NASDAQ in September 2017. Zai Lab has evolved from a pure licensing and development company into a commercial-stage biopharmaceutical enterprise with a growing portfolio of marketed products and an extensive pipeline of investigational therapies. The company focuses primarily on bringing innovative medicines to patients in China and other Asian markets, while also developing select assets for global markets.
Similar companies
Latest newsMore news →
Zai Lab announced that its DLL3-targeting antibody-drug conjugate zociluratug pelitecan (zoci) has advanced from an Investigational New Drug application to global Phase 3 development in under two years, with the DLLEVATE study evaluating it in second-line and later extensive-stage small cell lung cancer.27d agoZai Lab Limited announced its financial results for the second quarter of 2026, along with recent product highlights and corporate updates.30d agoThe U.S. FDA granted Orphan Drug Designation to Zai Lab's DLL3-targeting ADC zocilurtatug pelitecan for the treatment of neuroendocrine carcinomas.33d ago